Kirkland Advises Oaktree Acquisition Corp. II on Business Combination with Alvotech

Kirkland & Ellis advised Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (“Oaktree”), on its entry into a definitive business combination agreement with Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. The combined company is expected to have an implied initial enterprise value of approximately $2.25 billion. The transaction is currently expected to close in the first half of 2022.

Read the Oaktree press release

The Kirkland team was led by corporate partners Matthew Arenson and Michele Cumpston and associates Guirgis Nasief, Shannon Sherman and Michael Nester, capital markets partners Peter Seligson and Allison Gallagher and associates Wills Klein, Katrina Gonzales and Andrew Hao Sun, tax partners Mike Beinus and Vivek Ratnam and associate Liz Allison, and technology & IP transactions partner Matthew Lovell and associate Matt Darch.